相关实验视频
Updated: Jun 5, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
994
在轴性脊柱关节炎中使用JAK抑制剂的理由和担忧
Saad Ahmed1, Rohan Yesudian2, Hassan Ubaide1
1General Medicine, Colchester Hospital, Colchester, UK.
Rheumatology advances in practice
|December 11, 2024
概括
简氏激酶 (JAK) 抑制剂为轴性脊柱关节炎 (axSpA) 提供了新的治疗选择,对目前治疗不响应的患者显示有前途. 需要进一步的研究来确认长期的疗效和安全性,特别是在非放射性 axSpA.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 轴性脊椎关节炎 (axSpA) 是一种慢性炎症状况,治疗选择有限.
- 简氏激酶 (JAK) 抑制剂代表了一种新的治疗类,对axSpA.有着独特的作用机制.
研究的目的:
- 审查JAK抑制剂在治疗axSpA中的疗效和安全性.
- 总结axSpA中tofacitinib,upadacitinib和filgotinib的2期和3期临床试验的数据.
主要方法:
- 对目前的2期和3期临床试验数据进行系统审查,对托法西提尼布,乌帕达西提尼布和菲尔戈提尼布.
- 对安全概况的评估,包括来自ORAL监测研究等研究的新出现的安全信号.
主要成果:
- 雅克抑制剂在axSpA中表现出潜在的有效性,解决了对现有治疗不充分反应或禁忌的患者的未满足需求.
- 总结了涉及托法西提尼布,乌帕达西提尼布和菲尔戈提尼布的试验数据,突出了它们的治疗作用.
结论:
- 雅克抑制剂为axSpA提供了一种新的治疗途径,有可能改善特定患者群体的治疗结果.
- 需要进行进一步的长期研究,以充分确定JAK抑制剂的疗效和安全性,特别是在非放射性axSpA.
相关概念视频
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
115
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
385
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
385
Inflammatory Bowel Disease IV: Pharmacological Management
112
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
112
Antihypertensive Drugs: Direct Renin Inhibitors
490
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
490
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K

